BackNKGen Biotech Overview
NKGen Biotech Inc

NKGen Biotech Return on Equity

Valuation check: NKGN's ROE is 46.8%, above the sector sector average of -5.87%.

Get informed when a big investor buys or sells

+ Follow

ROE

46.80%

Return on Equity

46.80%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

NKGen Biotech (NKGN) FAQ

NKGen Biotech (NKGN) currently reports a ROE of 46.8%. That is above the sector sector average of -5.87%. Use the charts on this page to explore NKGen Biotech's ROE history and peer comparisons.

NKGen Biotech's ROE of 46.8% is higher than the its sector sector average of -5.87%. That is roughly 897.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but NKGen Biotech's current 46.8% should be judged against industry norms (sector average: -5.87%) and against NKGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 46.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.87%. From there, open related valuation or income-statement pages for NKGen Biotech, and consider following NKGN for alerts when major investors trade the stock.